SCHEMBL19228048

SCHEMBL19228048

CNS(=O)(=O)CCC(=O)N[C@H]1Cc2cccc(C(O)O)c2OB1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18797961 0.90 — —
SCHEMBL23129882 0.89 — —
SCHEMBL22667458 0.86 MAPT (0.33) —
SCHEMBL22667381 0.86 MTNR1A (0.41) —
SCHEMBL17336987 0.85 ACLY (0.31) —
SCHEMBL17336985 0.85 ACLY (0.31) —
SCHEMBL23130138 0.85 ADRA2A (0.33) —
SCHEMBL23837376 0.84 SMYD3 (0.34) —
SCHEMBL19228027 0.84 AAK1 (0.34) —
SCHEMBL19663642 0.83 MAPT (0.34) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9783555-B2 Beta-lactamase inhibitors VenatoRx Pharmaceuticals, Inc. (US) 2017-10-10 — — US disclosed
US-20170226135-A1 BETA-LACTAMASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-08-10 — — US disclosed
Send feedback